Rankings
▼
Calendar
▼
CYCN Q3 2018 Earnings Report — Cyclerion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
Cyclerion Therapeutics, Inc.
CYCN
Q3 2018 Earnings
Reported September 29, 2018
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q3 2018
Q2 2018
Q3 2017
QoQ Change
YoY Change
Revenue
$0
$0
$0
—
—
Op. Income
-$29M
-$30M
-$25M
1.7%
-16.3%
EPS (Diluted)
$-21.45
$-21.81
$-18.38
1.7%
-16.7%
Free Cash Flow
-$26M
-$23M
—
-15.5%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$21M
Selling & Marketing
$0
General & Administrative
$8M
SG&A Expenses
$8M
Other Expenses
$0
Operating Expenses
$29M
Cost & Expenses
$29M
OPERATING INCOME
-$29M
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$29M
Income Tax Expense
$0
Net Income from Continuing Ops
-$29M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$29M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$29M
D&A
$340.0K
EBIT
-$29M
EBITDA
-$29M
EPS
-$21
EPS Diluted
-$21
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$29M
Depreciation & Amortization
$340.0K
Stock-Based Compensation
$3M
Deferred Income Tax
$0
Other Non-Cash Items
$0
Change in Working Capital
$331.0K
OPERATING CASH FLOW
-$25M
Capital Expenditure
-$1M
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$1M
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$26M
NET CASH FROM FINANCING
$26M
FREE CASH FLOW
-$26M
Net Change in Cash
$0
marketcaparena.com
← FY 2018
CYCN Overview
Q4 2018 →